G1 Therapeutics, Inc.
GTHX · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $130 | $237 | $158 | $75 |
| - Cash | $15 | $20 | $32 | $94 |
| + Debt | $48 | $47 | $57 | $5 |
| Enterprise Value | $162 | $265 | $183 | -$15 |
| Revenue | $17 | $14 | $15 | $12 |
| % Growth | 14.3% | -2.7% | 20.9% | – |
| Gross Profit | $16 | $13 | $14 | $9 |
| % Margin | 95.6% | 92.5% | 91.6% | 75% |
| EBITDA | -$3 | -$8 | -$8 | -$15 |
| % Margin | -15.8% | -56.1% | -52% | -122.4% |
| Net Income | -$5 | -$10 | -$11 | -$18 |
| % Margin | -33.1% | -70.6% | -73.1% | -148% |
| EPS Diluted | -0.1 | -0.2 | -0.21 | -0.35 |
| % Growth | 50% | 4.8% | 40% | – |
| Operating Cash Flow | -$5 | -$9 | -$13 | -$11 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$5 | -$9 | -$13 | -$11 |